2025-08-12
Tofacitinib citrate is an innovative Janus kinase (JAK) inhibitor that has revolutionized the treatment of several autoimmune conditions. This comprehensive guide explores the clinical applications, pharmacological mechanism, dosage forms, and safety profile of Tofacitinib citrate, providing healthcare professionals with essential information about this breakthrough medication developed by Run'an Pharmaceutical.
Tofacitinib citrate is FDA-approved for multiple therapeutic indications with proven efficacy in:
1. Rheumatoid Arthritis (RA)Moderate to severe active RA in adults
Methotrexate combination or monotherapy
Reduces joint swelling and progression of structural damage
Active PsA in patients with inadequate response to DMARDs
Improves enthesitis and dactylitis
Moderate to severe active UC
Induction and maintenance of remission
Ankylosing spondylitis
Alopecia areata
Juvenile idiopathic arthritis
Indication | Dosage Form | Recommended Dose | Treatment Duration |
---|---|---|---|
Rheumatoid Arthritis | Tablet (5mg) | 5mg twice daily | Long-term |
Psoriatic Arthritis | Tablet (5mg) | 5mg twice daily | Long-term |
Ulcerative Colitis | Extended-release (11mg) | 11mg once daily | Induction: 8 weeks |
Tofacitinib citrate exerts its therapeutic effects through:
JAK-STAT Pathway InhibitionSelective inhibition of JAK1 and JAK3
Modulation of cytokine signaling (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21)
Reduction of inflammatory mediators
Decreases circulating CD16+/CD56+ NK cells
Reduces serum C-reactive protein (CRP) levels
Lowers matrix metalloproteinase (MMP) levels
Cell Type | Effect | Clinical Outcome |
---|---|---|
T Cells | Reduced proliferation | Decreased inflammation |
B Cells | Limited activation | Lower autoantibody production |
Macrophages | Inhibited activation | Reduced tissue damage |
Upper respiratory tract infections (15-20%)
Headache (4-7%)
Diarrhea (3-5%)
Increased LDL cholesterol (10-15%)
✔ Herpes zoster reactivation
✔ Thromboembolic events
✔ Lymphoma and other malignancies
✔ Gastrointestinal perforations
✔ cGMP-certified manufacturing facilities
✔ Strict quality control exceeding pharmacopeial standards
✔ Comprehensive stability studies
✔ Global regulatory compliance (FDA, EMA, PMDA)
✔ Competitive pricing for healthcare systems
For product information, clinical data, or partnership opportunities:
As the Chief Scientific Officer at Run'an Pharmaceutical with 20 years of experience in immunomodulatory therapies, I personally guarantee the quality and efficacy of our Tofacitinib citrate formulations. Contact our medical affairs team today to discuss how we can support your therapeutic needs.